Funded Projects › FP7
PREDICT-IV · Profiling the toxicity of new drugs: a non animal-based approach integrating toxicodynamics and biokinetics
The overall aim of Predict-IV is to develop strategies to improve the assessment of drug safety in the early stage of development and late discovery phase, by an intelligent combination of non animal-based test systems, cell biology, mechanistic toxicology and in-silico modelling, in a rapid and cost effective manner. A better prediction of the safety of an investigational compound in early development will be delivered. Margins-of-safety will be deduced and the data generated by the proposed approach may also identify early biomarkers of human toxicity for pharmaceuticals. The results obtained in Predict-IV will enable pharmaceutical companies to create a tailored testing strategy for early drug safety. The project will integrate new developments to improve and optimize cell culture models for toxicity testing and to characterize the dynamics and kinetics of cellular responses to toxic effects in vitro. The target organs most frequently affected by drug toxicity will be taken into account, namely liver and kidney. Moreover, predictive models for neurotoxicty are scarce and will be developed. For each target organ the most appropriate cell model will be used. The approach will be evaluated using a panel of drugs with well described toxicities and kinetics in animals and partly also in humans. This approach will be highly advantageous as it will allow a direct comparison between the in vivo to the in vitro data. A parallel analysis of several dynamic and kinetic models with a broad spectrum of endpoints should allow for the identification of several relevant biomarkers of toxicity. Inter-individual susceptibilities will be taken into account by integrating the polymorphisms of the major drug metabolizing enzymes and correlating the observed effects in the human cell models with their genotype. Environmental influences on cellular toxicity to these compounds will also be evaluated using hypoxic stress as a relevant test model.
Consortium · 20 organisations
JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURG
DE · €1,638,469
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
IE · €482,652
NEUROPROOF GMBH
DE · €311,173
UNIVERSITE DE LAUSANNE
CH · €471,862
CERTARA UK LIMITED
UK · €245,199
INSTITUT NATIONAL DE L ENVIRONNEMENT INDUSTRIEL ET DES RISQUES - INERIS
FR · €446,167
NOVARTIS PHARMA AG
CH · €800,496
ISTITUTO SUPERIORE DI SANITA
IT · €436,152
DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERG
DE · €346,784
PARIS-LODRON-UNIVERSITAT SALZBURG
AT · €850,096
MEDIZINISCHE UNIVERSITAT INNSBRUCK
AT · €918,216
UNIVERSITAET ROSTOCK
DE · €551,202
UNIVERSITEIT UTRECHT
NL · €369,347
UNIVERSITE D'ARTOIS
FR · €395,811
FREIE UNIVERSITAET BERLIN
DE · €268,928
UNIVERSITE DE RENNES I
FR · €352,512
KaLy-Cell
FR · €548,380
EMERGENTEC BIODEVELOPMENT GMBH
AT · €875,160
Merck KGaA
DE · €873,974
JRC -JOINT RESEARCH CENTRE- EUROPEAN COMMISSION
BE · €148,326
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.